Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Safety of anti-TNF agents during pregnancy in IBD

The most recent issue of the American Journal of Gastroenterology investigates the safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.

News image

Anti-tumor necrosis factor (TNF) drugs are an effective therapeutic option in patients with inflammatory bowel disease (IBD).

However, data regarding their safety during pregnancy and breastfeeding are scarce.

Dr Javier Gisbert and colleagues from Spain critically reviewed available data on the safety of anti-TNF therapy during pregnancy and breastfeeding in women with IBD.

The research team performed bibliographical searches (MEDLINE) up to 2013.

The studies included provided data from 462 women with IBD exposed to anti-TNF agents during pregnancy.

Anti-TNF drugs have been detected in breast milk
American Journal of Gastroenterology

Although these drugs cross the placenta from the end of the second trimester, they are low-risk in the short term.

The research team found that the use of anti-TNF agents after the second trimester leads to intra-uterine exposure.

An increase in infections has recently been observed in infants exposed to immunomodulators plus anti-TNF drugs in utero, thus raising concerns about the consequences for the development of the immune system.

Accordingly, it has recently been suggested that anti-TNF drugs should be stopped during the second trimester.

Certolizumab is a Fab fragment of an anti-TNF monoclonal antibody, and, therefore, it may not be necessary to stop it during pregnancy.

The team noted that anti-TNF drugs have been detected in breast milk, although in miniscule amounts.

Case reports do not suggest toxicity.

However, the team found that the effects of exposure on the neonate merit further investigation.

Dr Gisbert's team concludes, "Anti-TNF drugs can cross the placenta from the latter part of the second trimester of gestation, although they seem to be safe, at least in the short term."

"Miniscule amounts of anti-TNF drugs are transferred in breast milk; therefore, a deleterious effect of this exposure on the neonate, although unlikely, cannot be excluded."

Am J Gastroenterol 2013; 108:1426–1438
02 October 2013

Go to top of page Email this page Email this page to a colleague

 06 July 2015

Advanced search
 06 July 2015 
Future colorectal surgery for metachronous cancers
 06 July 2015 
Fecal microbiota transplantation
 06 July 2015 
Liver Failure–Sequential Organ Failure Scoring System
 03 July 2015 
Tumors with mismatch-repair deficiency
 03 July 2015 
Aptitude of trainees in endoscopic ultrasonography
 03 July 2015 
Extracolonic pathologies in colorectal cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Health care use by IBD children
 02 July 2015 
Anastomotic leak and cancer cancer
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Oral mechanical bowel preparation
 01 July 2015 
Probiotics in IBD
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 29 June 2015 
Rescue therapy in ulcerative colitis
 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 25 June 2015 
Fecal microbiota in pediatric IBD
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 24 June 2015 
Environmental risk in IBD
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
NAFLD risk in celiac disease
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us